Article

Blood Test Could Be Alternative to Cancer Biopsy

In the usual cancer biopsy, a surgeon cuts out a piece of the patient's tumor, but researchers in labs across the country are now testing a potentially transformative innovation. They call it the liquid biopsy.

cancer

biopsy

In the usual , a surgeon cuts out a piece of the patient’s tumor, but researchers in labs across the country are now testing a potentially transformative innovation. They call it the liquid biopsy, and it is a blood test that has only recently become feasible with the latest exquisitely sensitive techniques. It is showing promise in finding tiny snippets of cancer DNA in a patient’s blood.

CT scan

The hope is that a simple blood draw—far less onerous for patients than a traditional biopsy or a —will enable oncologists to quickly figure out whether a treatment is working and, if it is, to continue monitoring the treatment in case the cancer develops resistance. Failing treatments could be abandoned quickly, sparing patients grueling side effects and allowing doctors to try alternatives.

“This could change forever the way we follow up not only response to treatments but also the emergence of resistance, and down the line could even be used for really early diagnosis,” said José Baselga, MD, physician in chief and chief medical officer at Memorial Sloan Kettering Cancer Center.

Read more at The New York Times: http://nyti.ms/1IZS0Ha

Related Videos
Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program
Sandra Cuellar, PharmD
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Corey McEwen, PharmD, MS
dr linda bosserman
dr andrew leitner
Glenn Balasky during a video interview
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo